IO Biotech (IO Biotech) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. IO Biotech's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. IO Biotech's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.60.

IO Biotech Accounts Receivable Historical Data

The historical data trend for IO Biotech's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Accounts Receivable Chart

IO Biotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

IO Biotech Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial												-	-	-	-	-

IO Biotech Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

IO Biotech Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

IO Biotech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), IO Biotech's accounts receivable are only considered to be worth 75% of book value:

IO Biotech's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(117.982	+	0.75 * 0	+	0.5 * 0	-	12.693
-	0	-	0)	/	65.8809
=	1.60

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

IO Biotech Accounts Receivable Related Terms

Thank you for viewing the detailed overview of IO Biotech's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

IO Biotech (IO Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200

Website

https://www.iobiotech.com

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Executives

Brian Burkavage	officer: Chief Accounting Officer	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma	10 percent owner	24 RUE ROYALE, PARIS I0 75008
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith	officer: General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad	officer: Chief Medical Officer	1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan	officer: Chief Financial Officer	38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier	director	1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson	director	1209 ORANGE STREET, WILMINGTON DE 19801